Loading ...FDA Early Communication About the Safety of Lantus (Insulin Glargine)
July 8th, 2009 | 
Author: 07/01/2009
Lantus Has Been Linked to Increased Risk of Cancer
FDA is aware of four recently-published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies suggest an increased risk for cancer associated with use of Lantus. See http://www.diabetologia-journal.org/cancer.html.
Based on the currently available data, the FDA recommends that patients should not stop taking their insulin therapy without consulting a physician, since uncontrolled blood sugar levels can have both immediate and long-term serious adverse effects. Patients should also contact their healthcare professional if they have concerns about the medicines they are taking.
Source: FDA Advisory
Posted in FDA Alerts, Recalls, Product Safety | Tags: cancer, fad advisory, fda alerts, insulin glargine, lantus
